Home Cart Sign in  
Chemical Structure| 881970-80-5 Chemical Structure| 881970-80-5

Structure of iMDK
CAS No.: 881970-80-5

Chemical Structure| 881970-80-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

iMDK is a PI3K inhibitor that targets the growth factor MDK (midkine) and can synergistically inhibit non-small cell lung cancer (NSCLC) when combined with MEK inhibitors, showing no significant toxicity to normal cells or mice, highlighting its potential for cancer research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of iMDK

CAS No. :881970-80-5
Formula : C21H13FN2O2S
M.W : 376.40
SMILES Code : O=C1C(C2=CN3C(SC(CC4=CC=C(F)C=C4)=C3)=N2)=CC5=C(O1)C=CC=C5

Safety of iMDK

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of iMDK

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MeT-5A 7.5, 15, 50 µM 72 hours To evaluate the effect of iMDK on the proliferation of MeT-5A cells, results showed significant inhibition of cell proliferation at the highest dose (50 µM). Cancer Gene Ther. 2024 Nov;31(11):1708-1720
MSTO-211H 7.5, 15, 50 µM 72 hours To evaluate the effect of iMDK on the proliferation of MSTO-211H cells, results showed significant inhibition of cell proliferation at the highest dose (50 µM). Cancer Gene Ther. 2024 Nov;31(11):1708-1720
colon cancer cell line HCT116 100nM 48 hours Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis Front Oncol. 2022 Jun 7;12:885656
breast cancer cell line BT549 100nM 48 hours Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis Front Oncol. 2022 Jun 7;12:885656
cervical carcinoma cell line CaSki 100nM 48 hours Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis Front Oncol. 2022 Jun 7;12:885656
lung cancer cell line A549 100nM 48 hours Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis Front Oncol. 2022 Jun 7;12:885656
kidney cancer cell line Caki-1 100nM 48 hours Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis Front Oncol. 2022 Jun 7;12:885656
HUVEC cells 10 μM 5 hours To evaluate the effect of iMDK on HUVEC tube formation, results showed that iMDK combined with PD0325901 significantly inhibited tube formation Exp Cell Res. 2015 Jul 15;335(2):197-206
A549 cells 0.25 μM 72 hours To evaluate the inhibitory effect of iMDK on A549 cell proliferation, results showed that iMDK alone did not inhibit cell proliferation, but significantly inhibited cell proliferation when combined with PD0325901 Exp Cell Res. 2015 Jul 15;335(2):197-206
H520 cells 0.125 μM 72 hours To evaluate the inhibitory effect of iMDK on H520 cell proliferation, results showed that iMDK significantly inhibited cell proliferation Exp Cell Res. 2015 Jul 15;335(2):197-206
H2009 cells 1 μM 24 hours To evaluate the effect of iMDK on H2009 cell colony formation, results showed that iMDK significantly reduced colony formation Exp Cell Res. 2015 Jul 15;335(2):197-206
H441 cells 2.5 μM 72 hours To evaluate the inhibitory effect of iMDK on H441 cell proliferation, results showed that iMDK significantly inhibited cell proliferation Exp Cell Res. 2015 Jul 15;335(2):197-206
SKOV3 human ovarian cancer cell line 100 nM To assess the effect of iMDK on IFN-γ-induced EMT and metastasis, found that iMDK significantly suppressed IFN-γ-driven EMT and metastasis Biomedicines. 2022 Dec 21;11(1):8
SKOV3 human ovarian cancer cell line 6.6 nM 48 hours To assess the effect of iMDK on IFN-γ-induced anti-proliferation, found that iMDK significantly enhanced the anti-tumor activity of IFN-γ Biomedicines. 2022 Dec 21;11(1):8
NHLF normal human lung fibroblast cells 5-500 nM 48 hours iMDK had no significant effect on NHLF cells PLoS One. 2013 Aug 16;8(8):e71093
A549 lung adenocarcinoma cells 5-500 nM 48 hours iMDK had no significant effect on A549 cells PLoS One. 2013 Aug 16;8(8):e71093
H520 human lung squamous cell carcinoma cells 5-500 nM 48 hours iMDK inhibited H520 cell growth PLoS One. 2013 Aug 16;8(8):e71093
H441 lung adenocarcinoma cells 5-500 nM 48 hours iMDK inhibited H441 cell growth by suppressing the PI3K pathway and inducing apoptosis PLoS One. 2013 Aug 16;8(8):e71093
Caco-2 cells 25 nM 72 hours To investigate the effect of iMDK on the permeability of tight junctions in MPA-treated Caco-2 cell monolayers. Results showed that iMDK significantly inhibited MPA-induced compromised TJ integrity. Front Physiol. 2017 Jun 26;8:438
neural progenitors (NP) 0.5 μM 5 days Evaluate the effect of idebenone on NP cell viability, showing no significant change at 0.5 μM concentration. Biogerontology. 2017 Aug;18(4):665-677
early neural progenitors (eNP) 0.5 μM 5 days Evaluate the effect of idebenone on eNP cell viability, showing a significant increase to 138.19% at 0.5 μM concentration. Biogerontology. 2017 Aug;18(4):665-677
neural stem cells (NSC) 0.5 μM 5 days Evaluate the effect of idebenone on NSC cell viability, showing a significant increase to 130% at 0.5 μM concentration. Biogerontology. 2017 Aug;18(4):665-677

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Xenograft model Intraperitoneal injection 9 mg/kg Once every two days IMDK significantly reduced tumor volume and weight and decreased lung metastasis rates Cancers (Basel). 2020 Aug 24;12(9):2402
BALB/c nude mice H441 cell xenograft model IMDK: intraperitoneal injection, PD0325901: oral administration iMDK: 9 mg/kg, PD0325901: 5 mg/kg IMDK: once daily, PD0325901: five times per week, for 11 days To evaluate the inhibitory effect of iMDK combined with PD0325901 on H441 cell xenograft tumor growth, results showed that the combination therapy significantly inhibited tumor growth and tumor-associated angiogenesis Exp Cell Res. 2015 Jul 15;335(2):197-206
BALB/c nude mice H441 lung adenocarcinoma xenograft model Intraperitoneal injection 9 mg/kg 3 or 5 times per week for 10 days IMDK significantly inhibited tumor growth by suppressing the PI3K pathway and inducing apoptosis PLoS One. 2013 Aug 16;8(8):e71093

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.28mL

2.66mL

1.33mL

26.57mL

5.31mL

2.66mL

 

Historical Records

Categories